Enlivex Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Enlivex'in kazançlarının yıllık 147.8% oranında azalacağı tahmin edilmektedir. EPS'nin azalması yıllık 149.7% oranında azalması beklenmektedir.

Anahtar bilgiler

-147.8%

Kazanç büyüme oranı

-149.66%

EPS büyüme oranı

Biotechs kazanç büyümesi	24.7%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	23 Apr 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Oct 07

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Jun 19

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Mar 01

We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Sep 13

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Apr 04

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Dec 13

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Jul 25

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Apr 05

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analiz Makalesi • Nov 16

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Sep 30

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Summary Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders. All in all, the risk/reward profile justifies a small bet. Enlivex Therapeutics (ENLV) is a clinical stage pharmaceutical company developing a single drug candidate called Allocetra—an off-the-shelf, scalable, and affordable cell therapy which has been designed to reprogram macrophages in order to return them to their homeostatic state. It is currently being tested for life-threatening conditions such as sepsis and solid tumors, both as a standalone monotherapy and in combination with other therapies. The approach of ENLV is to target macrophages, a type of white blood cell that performs immune system functions such as removing dead cells from the body, engulfing and eliminating intrusive and harmful microbes that have entered the body, and activating other immune system cells. Sepsis is the body’s extreme response to an infection, whereby chemicals released in the blood to fight infection can trigger extreme inflammation in other parts of the body, potentially leading to organ failure. Like patients suffering from cancer, mortality rates for sepsis patients can be high. ENLV researchers believe that the macrophages of sepsis and solid tumor patients are out of their normal homeostatic state, and rather than engaging in anti-inflammation, pro-organ restoration, and anti-tumor activities, are instead engaging in pro-inflammation, pro-organ failure, and pro-tumor activities. The goal of Allocetra is to correct this imbalance and return macrophages to their homeostatic levels, which should reduce rates of drug resistance in patients and lead to better rates of disease resolution. Allocetra is a cell therapy, which refers to the practice of placing new cells into the patient’s body. After collecting cells from healthy donors, ENLV chemically modifies these donor cells using their proprietary process. The intent is to prompt the donor cells to send out an “eat me” signal, which is accomplished by expressing the biomarker phosphatidylserine, commonly known as “PtdSer.” Once the donor cells are placed into the patient’s body, the “eat me” signal attracts the macrophages in the surrounding inflamed area, which then engulf the donor cells. The engulfed donor cells then communicate with the macrophages while inside of them, and reprogram them in order to return them to their homeostatic state. ENLV’s method of communicating with the macrophages is proprietary, and forms the basis of their differentiated mechanism of action. To date, the only results in humans that we have for Allocetra were published on September 30, 2021 in the journal Frontiers In Immunology. As you can see in Table 1 on page 4, of the ten sepsis-treated patients, all of them lived, and their sepsis and organ dysfunction were resolved. Frontiers In Immunology; 9/30/21; pg 4 It does need to be pointed out that while the control group had a mortality rate of 27% (n=10/37), the phase 1b trial was run using a matched historical control. While this does not necessarily invalidate the results, using a matched historical control group is not as ideal as running a trial with simultaneous control and treatment groups. However, the currently-recruiting phase 2 sepsis trial will be a randomized, placebo-controlled, double-blind study. If the results can be replicated in phase 2, then this should alleviate investor concerns regarding the use of a historical control group in phase 1b. Thus far, all the solid tumor data we have is from animal models. But a quick glance at the results should make the potential impact of Allocetra very clear. ENLV ran the solid tumor study in mice suffering from mesothelioma, an aggressive and deadly form of cancer that occurs in the thin layer of tissue covering the majority of internal organs. In addition to Allocetra, the study incorporated the immune checkpoint inhibitor anti-CTLA4. The five groups analyzed were: mesothelioma (no treatment), mesothelioma + anti-CTLA4, mesothelioma + Allocetra (high dose), mesothelioma + anti-CTLA4 + Allocetra (low dose), and mesothelioma + anti-CTLA4 + Allocetra (high dose). On slide 30 of the company’s September 12, 2022 investor presentation, we can see clearly the encouraging results. By day 81, all eight of the mice in the no-treatment group had succumbed to the cancer. In the anti-CTLA4 group, only two of the eight mice were still alive, which was similar to the result of the high-dose Allocetra group (two of seven still alive). In the combo group of anti-CTLA4 + Allocetra (low dose), six of the nine mice were still alive. And finally, in the combo group of anti-CTLA4 + Allocetra (high dose), not only were all nine of the mice still alive, but all nine had a miraculous 100% cure rate. Company Presentation; 9/12/22; Slide 30 Any seasoned biotech investor knows that the number of companies that have shown very promising results in animal models that did not translate into the same results in humans are too numerous to count. Thus, these incredible results should be taken with a very large grain of salt. But a 100% survival rate and a 100% cure rate in the mouse model is startling, and clearly shows the synergistic potential of Allocetra when combined with another cancer-fighting agent. At a minimum, the mouse model results are certainly deserving of further investigation. On April 29, ENLV filed their 20-F Annual Report, which shows the number of ordinary shares beneficially owned by company insiders (it needs to be emphasized that the number of ordinary shares beneficially owned includes outstanding options and warrants to purchase ordinary shares). As of March 31, 2022, company insiders owned approximately 12% of the outstanding ordinary shares (see pg. 82), with Executive Chairman Shai Novak owning almost 7% on his own. 2021 20-F Annual Report Of Mr. Novak’s 1.3M potential shares, about 133K options have an exercise price of $2.69/share, and 174K have an exercise price of $3.66/share, with both exercise prices being below the current share price of about $4.00/share (as of September 29). However, Mr. Novak’s remaining options consist of 145K with an exercise price of $6.22/share, as well as 104K with an exercise price of $12.23/share, with both of these exercise prices being well above the current price. It would have been preferable if the exercise prices of all options would have been significantly higher than the current share price, as a low exercise price does not create a very high hurdle for management to reach in order to cash out. But for new shareholders at least, this level of potential insider ownership can be seen as a positive. One thing that investors should certainly like is the offering price of last year’s capital raise. The $10M offering announced on February 9, 2021 after-hours was for 500K shares at a price of $20.00/share. This came at a 17% discount to the previous day’s close of $24.00/share. However, the stock had closed at $13.05/share on February 2, and after positive COVID data was announced on February 3, proceeded to climb up to $24.00/share over the next few days. Viewed in this light, the offering price of $20.00/share and the 17% discount do not seem so unfair to existing shareholders. Furthermore, an expanded offering was announced later that same evening on February 9, 2021. The offering was expanded due to overwhelming demand, was also done at $20.00/share, and raised an additional $46M. They announced second quarter results on August 22, and as of June 30, had cash and cash equivalents of $63M, which management expects to last through 3Q2024. This works out to a quarterly cash burn of about $7M. With Allocetra development still being at such an early stage, it’s very unlikely that they will finance future clinical expenses via debt offerings.

Seeking Alpha • Sep 06

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex Therapeutics (NASDAQ:ENLV) said the U.S. Patent and Trademark Office issued a notice of allowance for patent application covering methods of using Allocetra to inhibit or reduce cytokine release syndrome in patients undergoing chimeric antigen receptor (CAR) T-cell therapy. The company expects the new patent — application number 15/551,284 — will be issued by the end of Q1 2023. The intellectual property protection is expected through at least 2036, the company said in a Sept. 6 press release. The company noted that Allocetra is being developed as a universal, off-the-shelf cell therapy aimed to reprogram macrophages into their homeostatic state.

Seeking Alpha • Aug 29

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Enlivex Therapeutics (NASDAQ:ENLV) said on Monday the Japanese patent office issued a Notice of Allowance that will provide the company with added intellectual property protection through at least 2037, with claims covering the use of pooled donor cells as source materials for cell therapy, Allocetra. The Company expects the new patent to be issued in Japan by the second quarter of 2023. Enlivex is developing Allocetra as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state.

Seeking Alpha • Aug 22

Envilex Therapeutics reports Q2 results

Envilex Therapeutics press release (NASDAQ:ENLV): Q2 Net loss of $9.9M As of June 30, 2022, Enlivex had cash, cash equivalents, and short-term deposits of $62.5 million.

Analiz Makalesi • Jul 08

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Jul 06

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Israel-based Enlivex Therapeutics (NASDAQ:ENLV) on Wednesday said the first patient had been dosed in its phase 1/2 clinical trial evaluating its cell therapy Allocetra in combination with chemotherapy to treat cancer of the peritoneum. ENLV stock +7.5% at $4.90 in afternoon trading. The early-to-mid stage trial is expected to enroll about 12 patients across four cohorts and will evaluate the safety and potential preliminary efficacy of Allocetra in combination with chemotherapy in peritoneal cancer patients. This is the initiation of the company's first oncology trial, according to ENLV CEO Oren Hershkovitz. The trial is taking place at Israel's Sheba Medical Center hospital.

Analiz Makalesi • Mar 23

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Nov 25

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analiz Makalesi • Aug 12

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Apr 29

We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jan 11

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Nov 19

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

If you want to know who really controls Enlivex Therapeutics Ltd. (NASDAQ:ENLV), then you'll have to look at the...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ENLV - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	N/A	-25	N/A	N/A	1
12/31/2026	N/A	-20	N/A	N/A	1
12/31/2025	N/A	1,236	-10	-10	N/A
9/30/2025	N/A	-13	-12	-12	N/A
6/30/2025	N/A	-13	-13	-13	N/A
3/31/2025	N/A	-14	-13	-13	N/A
12/31/2024	N/A	-15	-13	-13	N/A
9/30/2024	N/A	-19	-14	-14	N/A
6/30/2024	N/A	-22	-17	-17	N/A
3/31/2024	N/A	-26	-22	-22	N/A
12/31/2023	N/A	-29	-24	-24	N/A
9/30/2023	N/A	-27	-26	-23	N/A
6/30/2023	N/A	-27	-28	-24	N/A
3/31/2023	N/A	-30	-34	-26	N/A
12/31/2022	N/A	-31	-32	-24	N/A
9/30/2022	N/A	-29	-32	-26	N/A
6/30/2022	N/A	-26	-29	-23	N/A
3/31/2022	N/A	-19	-21	-18	N/A
12/31/2021	N/A	-14	-19	-18	N/A
9/30/2021	N/A	-16	-18	-17	N/A
6/30/2021	N/A	-14	-16	-15	N/A
3/31/2021	N/A	-14	-15	-14	N/A
12/31/2020	N/A	-12	-12	-11	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-9	-7	-7	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-10	-7	-7	N/A
9/30/2019	N/A	-9	N/A	-6	N/A
6/30/2019	N/A	-7	N/A	-5	N/A
3/31/2019	N/A	-7	N/A	-3	N/A
12/31/2018	N/A	-5	N/A	-3	N/A
9/30/2018	N/A	-4	N/A	-3	N/A
12/31/2017	N/A	-3	N/A	-2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ENLV şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -147.8% ).

Kazançlar ve Piyasa: ENLV şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -147.8% ).

Yüksek Büyüme Kazançları: ENLV şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: ENLV şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: ENLV gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ENLV 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/07 22:53
Gün Sonu Hisse Fiyatı	2026/05/07 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Enlivex Ltd. 2 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jason Kolbert	D. Boral Capital LLC.
Raghuram Selvaraju	H.C. Wainwright & Co.

Enlivex Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 26% to US$7.00

Price target decreased by 20% to US$12.00

Price target decreased to US$15.00

Price target increased to US$33.00

Recent updates

Enlivex Ltd Announces Regulatory Approval for Phase 2B Trial of Allocetra in Age-Related Primary Moderate-To-Severe Knee Osteoarthritis

New major risk - Revenue and earnings growth

Enlivex Ltd. announced that it has received $19 million in funding from The Lind Partners, LLC

Enlivex Ltd Receives Ind Clearance for Phase 2B Trial of Allocetra in Age-Related Primary Moderate-To-Severe Knee Osteoarthritis

New minor risk - Share price stability

New major risk - Shareholder dilution

Enlivex Therapeutics Ltd. announced that it has received $9.5 million in funding

Enlivex Therapeutics Ltd. Announces Positive 6-Month Topline Data from the Phase I/Ii Allocetra™? Trial

Price target decreased by 26% to US$7.00

Enlivex Therapeutics Ltd. Announces the Appointment of Matteo Renzi to the Board of Directors, Effective November 24, 2025

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 10, 2025

Enlivex Therapeutics Ltd. Announces Strategic Roadmap Following Positive Phase IIa Allocetra Results

Enlivex Therapeutics Ltd. Announces Positive Topline Data from Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients with Moderate-To-Severe Knee Osteoarthritis

New minor risk - Share price stability

Enlivex Therapeutics Ltd. Reaffirms August 18, 2025 as Target Date for Announcement of Phase II Topline Data

New major risk - Financial position

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Enlivex Therapeutics Ltd. to Present Clinical Data of Allocetra in Osteoarthritis At Eular 25 European Congress of Rheumatology

Enlivex Announces Completion of Enrollment in the Phase I/II Trial Evaluating Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Therapeutics Ltd. to Provide Additional Intellectual Property Protection in China Through At Least 2040

Enlivex Therapeutics Ltd. Announces Positive Interim Data from the Phase I/II Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate

Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased by 20% to US$12.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

New major risk - Financial position

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$15.00

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Envilex Therapeutics reports Q2 results

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Price target increased to US$33.00

Insufficient new directors

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Independent Director notifies of intention to sell stock

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth